2025-04-06 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis

**0. Key Figures Summary:**

* **Cumulative Return (MRK):** 7.28%
* **Cumulative Return (VOO):** 71.02%
* **Return Difference (MRK vs VOO):** -63.7%
* **Relative Return Difference:** 29.6% (Indicates MRK's performance is relatively lower than VOO,  falling in the upper 29.6th percentile of historical relative performance against VOO.)
* **Current Price:** $81.47
* **RSI:** 15.92 (Oversold)
* **PPO:** -1.07 (Bearish)
* **Market Risk Indicator (MRI):** 0.47 (High Risk)


**1. Company Overview and Performance Comparison:**

Merck & Co Inc is a leading pharmaceutical company.  Over the period analyzed, MRK significantly underperformed the S&P 500 (VOO), exhibiting a substantial negative return difference of -63.7%.  This indicates MRK's substantial underperformance relative to the broader market.  The relative return difference of 29.6% reflects that this underperformance is relatively high compared to its historical performance relative to VOO.


**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 5.0% | 58.4% | -24.0% | 0.0 | 109.0 |
| 2016-2018  | 42.0% | 60.6% | 25.0% | 0.4 | 152.5 |
| 2017-2019  | 40.0% | 60.6% | 11.0% | 0.2 | 186.5 |
| 2018-2020  | 19.0% | 60.6% | -10.0% | 0.4 | 173.1 |
| 2019-2021  | -4.0% | 14.2% | -78.0% | 0.5 | 176.1 |
| 2020-2022  | 14.0% | 63.1% | -7.0% | 0.5 | 263.1 |
| 2021-2023  | 32.0% | 63.1% | 4.0% | 0.4 | 265.8 |
| 2022-2024  | -6.0% | 63.1% | -21.0% | 0.3 | 249.1 |
| 2023-2025  | -46.0% | 70.3% | -49.0% | 0.2 | 205.8 |

The data shows inconsistent performance with periods of strong positive alpha and periods of significant negative alpha. Beta generally stays relatively low.  The high negative alpha in recent years significantly contributes to underperformance relative to the S&P 500.


**2. Recent Price Movements:**

* **Closing Price:** $81.47
* **5-Day Moving Average:** $86.27
* **20-Day Moving Average:** $90.82
* **60-Day Moving Average:** $91.81

The stock price is significantly below all three moving averages, indicating a bearish trend.  The recent price change of -$5.7 from the previous close suggests a notable price drop.


**3. Technical Indicators and Expected Return:**

* **RSI:** 15.92 (Significantly oversold, suggesting potential for a bounce, but not necessarily a sustained uptrend.)
* **PPO:** -1.07 (Negative value indicates bearish momentum.)
* **Delta_Previous_Relative_Divergence:** +11.9 (Short-term upward trend in relative strength.)
* **Expected Return:** -61.4% (This extremely negative expected return warrants further investigation and potentially suggests significant risk.)
* **Market Risk Indicator (MRI):** 0.47 (High Risk)


The combination of low RSI and negative PPO signals an oversold condition and bearish momentum. The positive relative divergence suggests some short-term strength, but the overall picture is bearish, reinforced by the high MRI score and very negative expected return. The large negative price change highlights a recent sharp decline.


**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2024-11-06 | 1.25 | $16.66 B      |
| 2024-08-05 | 2.15 | $16.11 B      |
| 2024-05-03 | 1.88 | $15.78 B      |
| 2023-11-03 | 1.87 | $15.96 B      |
| 2024-11-06 | 1.87 | $15.96 B      |

There appears to be a duplicate entry for 2024-11-06.  Revenue remains relatively stable, but EPS shows significant volatility, with a notable drop in the most recent quarter. This volatility needs further investigation to determine the underlying causes.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |
| 2023-12-31 | $14.63B | 73.26% |

Revenue has been relatively stable, although it experienced a slight decline in the last quarter. Profit margins remain consistently high.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |
| 2024-06-30 | $43.58B | 12.52% |
| 2024-03-31 | $40.36B | 11.80% |
| 2023-12-31 | $37.58B | -3.26% |

Equity is increasing, but ROE shows considerable fluctuation. The negative ROE in 2023-12-31 is concerning.


**6. Overall Analysis:**

MRK is currently exhibiting a bearish trend, significantly underperforming the S&P 500. While the stock is technically oversold, the negative PPO, high MRI, and drastically negative expected return suggest substantial downside risk.  The recent earnings report reveals revenue stability but significant EPS volatility.  The fluctuating ROE and negative ROE in Q4 2023 require further examination.  Given the negative expected return of -61.4%, a long-term investment in MRK at this time requires careful consideration and a tolerance for significant risk. Further investigation into the reasons behind the recent underperformance and earnings volatility is crucial before making any investment decisions.
